Back to Journals » Lung Cancer: Targets and Therapy » Volume 4 » default

Lung Cancer: Targets and Therapy


Archive: Volume 4, 2013

Potential toxicity and safety evaluation of nanomaterials for the respiratory system and lung cancer

Vlachogianni T, Fiotakis K, Loridas S, Perdicaris S, Valavanidis A

Lung Cancer: Targets and Therapy 2013, 4:71-82

Published Date: 27 November 2013

Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases

Herder GJM, Codrington H, Colder CD, Aerts JG

Lung Cancer: Targets and Therapy 2013, 4:55-59

Published Date: 11 October 2013

Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer

Karam SD, Horne ZD, Hong RL, Baig N, Gagnon GJ, McRae D, Duhamel D, Nasr NM

Lung Cancer: Targets and Therapy 2013, 4:35-42

Published Date: 7 August 2013

EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?

Wang QS, Mou JH, Yang X, He Y, Li ZP, Luo QY, Li YQ, Lin L, Ma Y, Xiao HL

Lung Cancer: Targets and Therapy 2013, 4:27-33

Published Date: 1 July 2013

MET overexpression and gene amplification in NSCLC: a clinical perspective

Landi L, Minuti G, D'Incecco A, Salvini J, Cappuzzo F

Lung Cancer: Targets and Therapy 2013, 4:15-25

Published Date: 19 June 2013

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

Sugiura Y, Nemoto E, Kawai O, Ohkubo Y, Fusegawa H, Kaseda S

Lung Cancer: Targets and Therapy 2013, 4:9-14

Published Date: 10 June 2013

Targeted inhibition in tumors with ALK dependency

Kwak EL, Clark JW, Shaw AT

Lung Cancer: Targets and Therapy 2013, 4:1-8

Published Date: 10 January 2013